Juan‐carlos García‐pagán

Juan‐carlos García‐pagán's AcademicInfluence.com Rankings

Philosophy

#6564

World Rank

#9620

Historical Rank

Logic

#3713

World Rank

#4911

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Juan‐carlos García‐pagán's Degrees

Doctorate Medicine University of Barcelona

Why Is Juan‐carlos García‐pagán Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Juan‐carlos García‐pagán's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. (2005) (881)
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. (2007) (865)
Early use of TIPS in patients with cirrhosis and variceal bleeding. (2010) (844)
The clinical use of HVPG measurements in chronic liver disease (2009) (528)
Hemodynamic response to pharmacological treatment of portal hypertension and long‐term prognosis of cirrhosis (2003) (513)
EASL Clinical Practice Guidelines: Vascular diseases of the liver. (2016) (511)
Complications of cirrhosis. I. Portal hypertension. (2000) (486)
Budd-Chiari syndrome: a review by an expert panel. (2003) (474)
Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. (2006) (463)
Etiology, management, and outcome of the Budd-Chiari syndrome. (2009) (458)
Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. (2004) (452)
Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow‐up study (2010) (446)
Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. (1998) (419)
Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. (2013) (419)
Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems (1998) (378)
Baveno VII - Renewing consensus in portal hypertension. (2021) (363)
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. (2008) (354)
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. (2007) (345)
A histologic scoring system for prognosis of patients with alcoholic hepatitis. (2014) (337)
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. (2009) (328)
Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. (2009) (316)
The management of portal hypertension: rational basis, available treatments and future options. (2008) (311)
Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. (2012) (309)
TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. (2008) (301)
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation (2006) (292)
Early use of TIPS in patients with cirrhosis and variceal bleeding (2010) (273)
Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. (2004) (255)
Prevention of variceal rebleeding (2003) (249)
Good long‐term outcome of Budd‐Chiari syndrome with a step‐wise management (2013) (241)
Idiopathic noncirrhotic portal hypertension (2011) (241)
Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis (2006) (238)
[Portal vein thrombosis]. (2018) (226)
Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis (2015) (226)
Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: A multicenter survey on safety and efficacy (2013) (225)
Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. (2016) (223)
Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline (2016) (222)
Functional aspects on the pathophysiology of portal hypertension in cirrhosis. (2012) (219)
TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: A randomized controlled trial (2002) (219)
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis (2011) (213)
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. (2005) (212)
Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. (2009) (212)
TIPS is a useful long‐term derivative therapy for patients with Budd‐Chiari syndrome uncontrolled by medical therapy (2002) (207)
Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus–related cirrhosis (1999) (207)
Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. (2007) (203)
Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. (2017) (202)
Sinusoidal Endothelial Dysfunction Precedes Inflammation and Fibrosis in a Model of NAFLD (2012) (202)
Randomized comparison of long‐term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis (2002) (201)
Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis (2010) (199)
Real-time shear-wave elastography: applicability, reliability and accuracy for clinically significant portal hypertension. (2015) (196)
Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. (2010) (191)
Measurement of portal pressure and its role in the management of chronic liver disease. (2006) (189)
Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases (2020) (188)
Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study (2017) (182)
Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. (2012) (177)
Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet‐derived growth factor blockade in rats (2007) (175)
Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial (2016) (173)
Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. (2008) (172)
The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. (2013) (170)
Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis (2012) (168)
Antithrombotic treatment with direct‐acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis (2017) (168)
Portal hypertension and gastrointestinal bleeding. (2008) (160)
Carvedilol, a new nonselective beta‐blocker with intrinsic anti‐alpha1‐adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis (1999) (159)
Propranolol plus placebo versus propranolol plus isosorbide‐5‐mononitrate in the prevention of a first variceal bleed: A double‐blind RCT (2003) (158)
Noninvasive Prediction of Clinically Significant Portal Hypertension and Esophageal Varices in Patients With Compensated Liver Cirrhosis (2008) (156)
KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins (2014) (151)
Endoscopic band ligation in the treatment of portal hypertension (2005) (151)
Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension (2011) (146)
PTFE‐covered stents improve TIPS patency in Budd‐Chiari syndrome (2004) (145)
Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. (2004) (142)
Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis☆☆☆ (2001) (139)
Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. (2001) (135)
Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. (2012) (135)
Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis (2007) (132)
Animal models of portal hypertension. (2006) (130)
Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference (2018) (128)
Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. (2019) (125)
Effects of low‐sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis (1994) (123)
Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. (1997) (118)
Effect of Meal Ingestion on Liver Stiffness in Patients with Cirrhosis and Portal Hypertension (2013) (118)
Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. (2009) (115)
Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy (2006) (115)
Idiopathic portal hypertension: Natural history and long‐term outcome (2014) (114)
Preemptive‐TIPS Improves Outcome in High‐Risk Variceal Bleeding: An Observational Study (2018) (113)
Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension (2006) (112)
The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis (2006) (110)
Impact of anticoagulation on upper‐gastrointestinal bleeding in cirrhosis. A retrospective multicenter study (2015) (107)
Extrahepatic portal vein thrombosis. (2008) (106)
Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. (2012) (105)
Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. (2010) (104)
Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. (2010) (104)
Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. (2009) (103)
Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial (2009) (102)
Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. (1998) (100)
5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. (2002) (100)
Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C (2018) (99)
Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. (2001) (98)
Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers (2012) (97)
Inflammation and portal hypertension - the undiscovered country. (2014) (93)
Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension. (1990) (91)
Porto-sinusoidal vascular disease: proposal and description of a novel entity. (2019) (90)
Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. (2016) (89)
Patterns of vasoregulatory gene expression in the liver response to ischemia/reperfusion and endotoxemia. (1999) (89)
Management of gastric varices. (2014) (89)
Idiopathic Portal Hypertension in Patients With HIV Infection Treated With Highly Active Antiretroviral Therapy (2009) (88)
Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites (1994) (88)
Effects of simvastatin administration on rodents with lipopolysaccharide‐induced liver microvascular dysfunction (2013) (87)
Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis (2003) (87)
Nontumoral portal vein thrombosis in patients awaiting liver transplantation (2016) (86)
Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis (2013) (85)
Portal cholangiopathy: radiological classification and natural history (2011) (83)
Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats. (2006) (82)
Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis (1995) (81)
Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. (2018) (80)
Ascites after liver transplantation (2000) (79)
Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. (2020) (78)
Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. (2020) (76)
A prospective randomized trial of heater probe thermocoagulation versus injection therapy in peptic ulcer hemorrhage. (1996) (75)
Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes. (2009) (75)
Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. (2020) (75)
Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. (2010) (74)
Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. (1995) (73)
Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon‐Free Therapy (2019) (70)
Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: Comparison with the effects on portal pressure (1988) (69)
Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study (2020) (68)
Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. (2015) (68)
Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury. (2017) (67)
Imaging in clinical decision-making for portal vein thrombosis (2014) (67)
Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta‐analysis (2017) (65)
Liver sinusoidal endothelial dysfunction after LPS administration: a role for inducible-nitric oxide synthase. (2014) (64)
Acute and long‐term effects of inhaled iloprost in portopulmonary hypertension (2010) (63)
Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis (2016) (63)
Portal vein thrombosis: a predictable milestone in cirrhosis? (2009) (63)
Simvastatin maintains function and viability of steatotic rat livers procured for transplantation. (2013) (62)
Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. (2005) (61)
Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. (2008) (61)
Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. (2015) (60)
Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension (2016) (59)
NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats (2006) (59)
Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. (2019) (59)
Variceal and other portal hypertension related bleeding. (2013) (58)
Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy (1993) (57)
Sonography of the caudate vein: value in diagnosing Budd-Chiari syndrome. (2003) (55)
Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. (2020) (54)
Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis (2014) (53)
Where does TIPS fit in the management of patients with cirrhosis? (2020) (51)
Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis (2019) (50)
Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. (2012) (50)
The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique (2015) (50)
Sonography of Budd-Chiari syndrome. (2006) (49)
Acute Variceal Bleeding (2012) (48)
Current knowledge and management of portal vein thrombosis in cirrhosis. (2021) (48)
Effects of propranolol on arterial oxygenation and oxygen transport to tissues in patients with cirrhosis. (1990) (47)
The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. (2011) (46)
Utility of Color Doppler Ultrasonography Predicting TIPS Dysfunction (2005) (46)
Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension. (2017) (46)
Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. (2010) (44)
NCX-1000, a Nitric Oxide–Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study (2010) (43)
Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. (1992) (43)
Total effective vascular compliance in patients with cirrhosis. Effects of propranolol. (2002) (42)
Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. (2017) (42)
Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis. (2012) (42)
Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies (2017) (42)
Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis. (2011) (41)
Pregnancy in women with portal vein thrombosis: results of a multicentric European study on maternal and fetal management and outcome. (2012) (41)
Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. (2021) (39)
Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. (2015) (39)
Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd‐Chiari syndrome (2006) (39)
Terutroban, a TP‐receptor antagonist, reduces portal pressure in cirrhotic rats (2013) (39)
Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis (2015) (39)
Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2021 (2021) (39)
Transjugular Intrahepatic Portosystemic Shunt for Acute Variceal Bleeding: A Meta-analysis (2014) (38)
Refractory acute variceal bleeding: what to do next? (2010) (38)
Changes in HVPG predict hepatic decompensation in patients who achieved SVR to IFN-free therapy. (2019) (37)
Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review (2020) (37)
Mitochondria‐targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats (2017) (37)
Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. (2002) (36)
Portal Hypertension Secondary to Myelofibrosis: A Study of Three Cases (2005) (34)
Idiopathic Portal Hypertension (2018) (34)
The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis (2016) (32)
Effects of ritanserin, a selective and specific S2‐serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long‐term bile duct ligation (1993) (32)
Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapy (2016) (32)
Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort. (2019) (32)
Influence of beta‐2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis (2006) (31)
Acute variceal bleeding: risk stratification and management (including TIPS) (2018) (31)
Isosorbide-5-mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. (1999) (30)
Value of transient elastography measured with fibroscan in predicting the outcome of hepatic resection for hepatocellular carcinoma. (2015) (30)
Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators (J Hepatol 1985; 1: 325–337) (2004) (30)
Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. (2020) (30)
Endotipsitis: an emerging prosthetic-related infection in patients with portal hypertension. (2004) (30)
Treatment of Acute Bleeding (2010) (30)
Cardiovascular Risk Factors and Systemic Endothelial Function in Patients With Cirrhosis (2013) (29)
Insulin resistance in patients with cirrhosis and portal hypertension. (2012) (29)
Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation (2017) (29)
Metabolomics Discloses Potential Biomarkers for the Noninvasive Diagnosis of Idiopathic Portal Hypertension (2013) (29)
Patients whose first episode of bleeding occurs while taking a β-blocker have high long-term risks of rebleeding and death. (2012) (28)
Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation (2021) (26)
Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease (2019) (26)
Long‐term effects of distal splenorenal shunt on hepatic hemodynamics and liver function in patients with cirrhosis: Importance of reversal of portal blood flow (1992) (26)
Increased CD11b neutrophil expression in Budd–Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera (2004) (25)
106 EFFICACY AND SAFETY OF ANTICOAGULATION IN PATIENTS WITH CIRRHOSIS AND PORTAL VEIN THROMBOSIS (2012) (25)
Transjugular liver biopsy. (2014) (25)
Endoscopic Cyanoacrylate Injection vs BRTO for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial. (2021) (24)
Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis (2018) (24)
Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment—Is It Worth Measuring? (2019) (24)
2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data meta‐analysis (2020) (23)
A novel form of the human manganese superoxide dismutase protects rat and human livers undergoing ischaemia and reperfusion injury. (2014) (22)
Pregnancy in idiopathic non-cirrhotic portal hypertension: A multicentric study on maternal and fetal management and outcome. (2018) (21)
Decompensation in advanced non-alcoholic fatty liver disease may occur at lower hepatic venous pressure gradient levels that in patients with viral disease. (2021) (21)
Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. (2013) (21)
Proteomic analysis reveals that apolipoprotein A1 levels are decreased in patients with Budd-Chiari syndrome. (2011) (21)
Nicardipine increases hepatic blood flow and the hepatic clearance of indocyanine green in patients with cirrhosis. (1994) (20)
Effects of molsidomine, a long acting venous dilator, on portal hypertension. A hemodynamic study in patients with cirrhosis. (1991) (20)
[Portal hypertension: recommendations for evaluation and treatment: consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Center for Liver and Digestive Diseases(CIBERehd)]. (2012) (20)
Impact of prior portosystemic shunt procedures on outcome of liver transplantation. (2005) (20)
Role of gap junctions modulating hepatic vascular tone in cirrhosis (2014) (20)
Anticoagulant therapy for splanchnic vein thrombosis: A systematic review and meta-analysis. (2020) (20)
A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding (2020) (20)
Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis (2012) (19)
25 Value of hvpg predicting 5-day treatment failure in acute variceal bleeding. Comparison with clinical variables (2006) (19)
Portal vein thrombosis: yes or no on anticoagulation therapy. (2018) (19)
Next generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. (2020) (18)
Nitric Oxide and Portal Hypertension (2002) (18)
Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension. (2013) (17)
Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. (2021) (16)
Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis (2021) (16)
23 Nadolol+Isosorbide-5-mononitrate (NAD+ISMN) vs NAD+ISMN + endoscopic band ligation in the prevention of rebleeding in patients with cirrhosis. Preliminary results of a multicenter RCT (2006) (15)
Stenosis of the suprahepatic inferior vena cava as a complication of transjugular intrahepatic portosystemic shunt in Budd‐Chiari patients (2001) (15)
Endoscopic Cyanoacrylate Injection Versus Balloon‐Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial (2021) (15)
The Splanchnic Circulation in Cirrhosis (2007) (14)
New Insights into the Pathogenesis, Risk Factors, and Treatment of Portal Vein Thrombosis in Patients with Cirrhosis (2020) (14)
Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD. (2006) (14)
Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study (2019) (14)
Metabolomics as a diagnostic tool for idiopathic non‐cirrhotic portal hypertension (2016) (13)
Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. (2017) (13)
A Specialized, Nurse-Run Titration Clinic: A Feasible Option for Optimizing β-Blockade in Non–Clinical Trial Patients (2010) (12)
Unexpected disappearance of portal cavernoma on long-term anticoagulation. (2014) (12)
Management of the major complications of cirrhosis: Beyond guidelines. (2021) (12)
Prognosis of acute variceal bleeding: Is being on beta‐blockers an aggravating factor? A short‐term survival analysis (2015) (12)
992 AN EARLY DECISION FOR PTFE-TIPS IMPROVES SURVIVAL IN HIGH RISK CIRRHOTIC PATIENTS ADMITTED WITH AN ACUTE VARICEAL BLEEDING. A MULTICENTER RCT (2008) (12)
Non-invasive tests for clinically significant portal hypertension after HCV cure. (2022) (11)
Prevalence , and Clinical Significance of Abnormal ematologic Indices in Compensated Cirrhosis (11)
Portal hypertension. (1989) (11)
Clinical Manifestations and Management of Bleeding Episodes in Cirrhotics (2008) (10)
Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis (2019) (10)
Feasibility and safety of pancreatic islet transplantation in the liver by portal vein catheterization using the transjugular route. (2006) (10)
Primary prophylaxis of esophageal variceal bleeding in cirrhosis. (2008) (10)
Isosorbide-5-monitrate (ISMN) vs placebo (PLA) in the prevention of the first variceal bleeding (FVB) in patients with contraindications or intolerance to beta-blockers (2000) (10)
Effects of end‐to‐side portacaval shunt and distal splenorenal shunt on systemic and pulmonary haemodynamics in patients with cirrhosis (1999) (10)
[Portal vein thrombosis]. (2010) (10)
Propranolol plus molsidomine vs propranolol alone in the treatment of portal hypertension in patients with cirrhosis. (1996) (10)
Idiopathic noncirrhotic portal hypertension in HIV-infected patients. (2010) (9)
Non-selective beta-blockers in the prevention of first variceal bleeding. Is there any definite alternative? (2002) (9)
Trials and Tribulations: The Prevention of Variceal Rebleeding. (2015) (9)
Portal hypertension: Nonselective β-blockers in patients with refractory ascites (2011) (9)
Monitoring of HVPG during pharmacological therapy: Evidence in favor of the prognostic value of a 20% reduction (2004) (9)
Hemodynamic response to propranolol in patients with recurrent hepatitis C virus–related cirrhosis after liver transplantation: A case‐control study (2013) (9)
An early decission for PTFE-TIPS improves survival in high risk cirrhotic patients admitted with an acute variceal bleeding. A multicenter RCT (2008) (9)
Reply (2019) (9)
Stroke Volume Response to Liver Graft Reperfusion Stress in Cirrhotic Patients (2014) (8)
Effects of propranolol on venous compliance in conscious rats with pre-hepatic portal hypertension. (2006) (8)
Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis (2020) (8)
Prevention of recurrent variceal bleeding. (2008) (8)
Clinical events following TIPS: Correlation with hemodynamic findings (1995) (7)
Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature (2021) (7)
Spironolactone (Sp) decreases portal pressure in patients with compensated cirrhosis (1991) (7)
Coexpression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease. (2021) (7)
The resistance of the cirrhotic liver: a new target for the treatment of portal hypertension. 1985. (2004) (7)
Combination of MELD and lactate predicts death in patients treated with salvage TIPS for refractory variceal bleeding. (2021) (7)
Other clinical studyNoninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis (1995) (7)
Endoscopic hemostasis in acute esophageal variceal bleeding. (2014) (7)
Calculating Hepatic Venous Pressure Gradient: Feel Free to Stay Free. (2016) (6)
The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study (2022) (6)
Incidence and Natural Course of Portal Vein Thrombosis in Cirrhosis (2013) (6)
Fibrinogen γ’ and variation in fibrinogen gamma genes in the etiology of portal vein thrombosis (2013) (6)
130 Pharmacological reduction of portal pressure and long term risk of first variceal bleeding in patients with cirrhosis (2003) (6)
19 DARK CHOCOLATE ATTENUATES THE POST-PRANDIAL INCREASE IN HVPG IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION (2010) (6)
Anticoagulation in cirrhosis: Ready … set … wait! (2013) (6)
Obeticholic acid: A new light in the shadows treating portal hypertension? (2014) (6)
[236] ACUTE HVPG RESPONSE TO I. V. PROPRANOLOL AND RISK OF PORTAL HYPERTENSION RELATED BLEEDING (2007) (6)
Contrast‐enhanced CT and liver surface nodularity for the diagnosis of porto‐sinusoidal vascular disorder: A case‐control study (2022) (6)
Portal Hypertensive Bleeding (2019) (6)
Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. (2022) (6)
Congenital antithrombin deficiency in patients with splanchnic vein thrombosis (2019) (5)
Impact of SARS-CoV-2 Pandemic on Vascular Liver Diseases (2021) (5)
Esophageal Stents for Acute Variceal Bleeding: Expanding the Possibilities (2018) (5)
The Budd-Chiari syndrome. (2004) (5)
Obstruction of the Portal Vein (2008) (5)
Combination of Model for End‐Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding (2021) (5)
[Idiopathic non-cirrhotic portal hypertension]. (2015) (5)
Lack of effect of pentoxifylline on portal pressure and hepatic haemodynamics in cirrhosis (1990) (5)
100 TRANSLOCATION OF BACTERIAL DNA IS ASSOCIATED WITH WORSENING OF THE HYPERKINETIC SYSTEMIC CIRCULATION AND OF INTRA-HEPATIC ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CIRRHOTIC AND ASCITES (2009) (5)
Transvenous liver biopsies in marrow transplant recipients. (1995) (4)
Letter: improve survival! Place early pre-emptive TIPSS in high-risk variceal bleeders. (2020) (4)
Treatment of Acute Variceal Bleeding in 2021-When to Use Transjugular Intrahepatic Portosystemic Shunts? (2021) (4)
[Diagnosis and treatment of portal thrombosis in liver cirrhosis]. (2012) (4)
Reversal of portal blood flow after distal splenorenal shunt (DSRS). Relationship to hepatic encephalopathy and impaired liver function (1989) (4)
422 IDIOPATHIC PORTAL HYPERTENSION: IMPACT OF HEPATIC VEIN CATHETERIZATION AND TRANSIENT ELASTOGRAPHY ON ITS DIAGNOSIS (2010) (4)
Propranolol plus placebo versus propranolol plus isosorbide‐5‐mononitrate in the prevention of a first variceal bleed: a doubleblind RCT (2003) (4)
Measurement of Azygos Blood Flow (1991) (4)
Portal Hypertension Reverses Following Successful Antiviral Treatment for HCV: Fact or Fiction? (2018) (4)
[83] TREATMENT OF BUDD CHIARI SYNDROME WITH TIPS. LONG-TERM RESULTS IN 124 PATIENTS AND EVALUATION OF PROGNOSTIC FACTORS (2007) (3)
Thromboprophylaxis with heparin in hospitalized patients with cirrhosis: friend or foe (2014) (3)
Lack of Correlation Between Preoperative and Intraoperative Liver Hemodynamics: A Descriptive Analysis (2014) (3)
[Animal models for the study of portal hypertension]. (2006) (3)
Proximal Splenic Artery Embolization to Treat Refractory Ascites in a Patient With Cirrhosis (2021) (3)
Carvedilol (Carv) vs propranolol (Prop) in the long-term treatment ofportal hypertension (PH) (2000) (3)
[87] EFFICACY OF ANTIVIRAL THERAPY ON DISEASE PROGRESSION IN HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A RANDOMIZED CONTROLLED STUDY (2007) (3)
Budd-Chiari syndrome with short-length stenosis: still room for the angioplasty and wait-and-see strategy. (2019) (3)
Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension (2021) (3)
49 OSTEOPONTIN IS A NOVEL THERAPEUTIC TARGET IN PATIENTS WITH ALCOHOLIC HEPATITIS (2010) (3)
Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis (2022) (3)
Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis. (2022) (3)
Reply Letter 17‐2110.R2 (2018) (3)
107 EFFECTS OF SIMVASTATIN ADMINISTRATION ON LIVER MICROVASCULAR DYSFUNCTION INDUCED BY LPS (2011) (3)
LETTERS TO THE EDITOR: TRANSVENOUS LIVER BIOPSIES IN MARROW TRANSPLANT RECIPIENTS (1995) (3)
Simvastatin ammeliorates the increased hepatic vascular tone in patients with cirrhosis (2003) (3)
Management of an acute variceal bleeding episode (2012) (2)
[218] BACTERIAL TRANSLOCATION INDUCES PROINFLAMMATORY CYTOKINES AND WORSENS SYSTEMIC HEMODYNAMICS IN CIRRHOTIC PATIENTS WITH ASCITES (2007) (2)
Erratum: Noninvasive Prediction of Clinically Significant Portal Hypertension and Esophageal Varices in Patients With Compensated Liver Cirrhosis (2012) (2)
4 Inhibition of VEGF receptor-2 (VEGFR-2) signaling prevents portal-systemic collateral (PSC) vessel formation in rats with portal hypertension (PH) (2004) (2)
Liver Transplantation for Porto-Sinusoidal Vascular Liver Disorder: Long-term Outcome. (2022) (2)
Predicting Heart Failure After TIPS: Still More Questions Than Answers (2019) (2)
Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis (2021) (2)
Microparticles and paracrine signaling in portal hypertension: crucial conversations or idle chat? (2012) (2)
Management of Acute Variceal Bleeding in Patients with Cirrhosis: General Management, Drug Therapy, and Endoscopic Treatment (2016) (2)
Favorable effects of propranolol in patients with malfunctioning porto-caval or distal spleno-renal shunts (1989) (2)
Risk of non‐tumoural portal vein thrombosis in patients with HCV‐induced cirrhosis after sustained virological response (2021) (2)
Rivaroxaban Reduces Portal Hypertension in Cirrhotic Rats by Deactivating Hepatic Stellate Cells and Reducing Intrahepatic Microthrombosis (2016) (2)
Autoimmune biomarkers in porto‐sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology (2021) (2)
Session 4: Primary Prophylaxis for Variceal Bleeding (2007) (2)
Impact of lifestyle interventions targeting physical exercise and caloric intake on cirrhosis regression in rats. (2021) (2)
Risk factors of poor prognosis in patients with pyrrolidine alkaloids induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt (2021) (2)
O077 : Use of direct oral anticoagulants (DOACs) in patients with splanchnic vein thrombosis and/or cirrhosis (2015) (2)
Natural History and Management of Esophagogastric Varices in Chronic Non-Cirrhotic Non-Tumoral Portal Vein Thrombosis (2016) (2)
[Functional component of portal hypertension]. (2004) (2)
Portal Vein Thrombosis in Patients with Cirrhosis. Incidence and Factors Associated with Its Development (2016) (2)
590 ASSESSMENT OF SYSTEMIC ENDOTHELIAL FUNCTION IN PATIENTS WITH CIRRHOSIS: COMPARISON BETWEEN PERIPHERAL ARTERIAL TONOMETRY (PAT) AND BRACHIAL ARTERY VASODILATATION BY ULTRASOUND (BAUS) (2011) (1)
119 THE TRANSCRIPTION FACTOR KLF2 MEDIATES HEPATIC ENDOTHELIAL PROTECTION CONFERRED BY STATINS (2012) (1)
Editorial: measuring inflammatory and fibrotic components of portal hypertension – a non‐invasive hepatic venous pressure gradient? Authors’ reply (2016) (1)
An overview of current treatment methods for Budd–Chiari syndrome (2014) (1)
55 HEMODYNAMIC EFFECTS AND SAFETY OF ONE-MONTH SIMVASTATIN TREATMENT IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER TRIAL (2008) (1)
LIVER NAD ( P ) H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats (2007) (1)
Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding (2022) (1)
[Recommendations for the diagnosis and treatment of patients with Budd-Chiari syndrome]. (2004) (1)
PS-022-Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding (2019) (1)
260 SUCCESSFUL THERAPY WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN CAUSES A SUSTAINED DECREASE IN PORTAL PRESSURE IN PATIENTS WITH CHRONIC HEPATITIS C-RELATED CIRRHOSIS (2010) (1)
Failure to control variceal bleeding: definition matters. (2021) (1)
77 EMBOLIZATION OF LARGE SPONTANEOUS PORTOSYSTEMIC SHUNTS FOR REFRACTORY HEPATIC ENCEPHALOPATHY: A EUROPEAN MULTI-CENTER SURVEY ON SAFETY & EFFICACY (2013) (1)
Propranolol effectively decreases portal pressure in patients with tips dysfunction (2001) (1)
18 PROTEOMIC ANALYSIS IDENTIFIES P90RSK AS A NOVEL THERAPEUTIC TARGET IN PATIENTS WITH ALCOHOLIC HEPATITIS (2011) (1)
PERSPECTIVES IN CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Management of Gastric Varices (2014) (1)
O148 KLF2 UP-REGULATION DECREASES HEPATIC FIBROSIS AND AMELIORATES ENDOTHELIAL DYSFUNCTION IN CIRRHOTIC RATS (2014) (1)
Lymphocyte beta-2 adrenoceptors (LAR-B2), plasma catecholamines and haemodynamic response to propranolol (PROP) in patients with cirrhosis and portal hypertension. (1989) (1)
Letter: improve survival after variceal bleeding in cirrhosis—place pTIPS as early as possible after index bleed (2023) (1)
Drug Therapy in Primary and Secondary Prevention of Variceal Hemorrhage in Portal Hypertension (1995) (1)
Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis. (2023) (1)
Budd-Chiari Syndrome: Anticoagulation, TIPS, or Transplant (2020) (1)
What else we need (2004) (1)
Bone morphogenetic protein receptor 2 in patients with idiopathic portal hypertension (2012) (1)
Reply to: “The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites” (2021) (1)
Non-invasive measurement of HVPG using graph analysis based on dynamic contrast-enhanced ultrasound with ESAOTE MyLab: The CLEVER Study (2018) (1)
[Early transjugular intrahepatic portosystemic shunt: When, how and in whom?]. (2016) (1)
Long-term impact of HCV eradication after all-oral therapy in patients with clinical significant portal hypertension (2018) (1)
Incidence and factors predictive of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis. (2022) (1)
O075 : Assessment of the transjugular porto-systemic shunt (TIPSS) in the management of complications of noncirrhotic portal hypertension (2015) (1)
Reply: Correspondence Hepatology, Month 2015 (2016) (1)
Trombosis venosa portal (2012) (1)
Reply to: ''Splenic artery aneurysms, portal hypertension and pregnancy". (2019) (1)
Prevention of variceal rebleeding (2003) (1)
The combined chronic administratton of propranolol (Prop) and isosorbide-5-mononitrate (Is-5-Mn) achieve greater beneficial effects than either drug alone (1989) (1)
551 OPTIMAL TIMING OF ENDOSCOPY IS ASSOCIATED WITH LOWER 42-DAY MORTALITY IN VARICEAL BLEEDING (2019) (1)
Bacterial infections in cirrhotic patients with transjugular intrahepatic portosystemic shunt (2002) (1)
Session 5 ‒ Primary Prophylaxis (2008) (1)
504 EFFECTS OF THE COMBINED ADMINISTRATION OF SORAFENIB PLUS PROPRANOLOL ON PORTAL HYPERTENSION IN CIRRHOTIC RATS (2010) (1)
[Covered transjugular intrahepatic portosystemic shunts]. (2006) (1)
The anticoagulant efficacy of rivaroxaban may be attenuated in cirrhotic patients (2017) (1)
256 ONE MONTH CAFETERIA DIET INDUCES NAFLD AND LIVER SINUSOIDAL ENDOTHELIAL DYSFUNCTION IN RATS (2008) (1)
Factors Predicting Survival In Patients With `Non-High-Risk' Acute Variceal Bleeding Receiving Nsbb And/Or Ebl To Prevent Re-Bleeding (2019) (1)
P0020 : Role of endothelial autophagy in liver Ischemia and Reperfusion injury (2015) (0)
The maintenance of increased glucagon levels preclude the effects of somatostatin on splanchnic haemodynamics in portal hypertensive rats (1989) (0)
210 SUSTAINED VIROLOGICAL RESPONSE WITH PEG-INTERFERON alfa-2a AND RIBAVIRIN DECREASES PORTAL PRESSURE GRADIENT AND PREVENTS CLINICAL DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C RELATED CIRRHOSIS (2013) (0)
Reply to: Letter to the Editor: Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. (2021) (0)
Role and Modulation of Nitric Oxide in the Cirrhotic Liver (2014) (0)
Nonendoscopic management of acute esophageal variceal bleeding (2017) (0)
Hepatocyte microvesicle levels predict 6-month survival in patients with cirrhosis: results of a prospective study on 242 patients (2017) (0)
A simple nomogram identifies patients with refractory ascites with worse outcome after transjugular intrahepatic portosystemic shunt (2021) (0)
Clinical course and treatment of incidentally detected splanchnic vein thrombosis: an individual patient data meta-analysis. (2023) (0)
Dynamic increase of intrahepatic vascular resistance in cirrhosis (2008) (0)
AASLD Program (2007) (0)
Metabolomics as a tool to predict the risk of decompensation or liver related death in patients with compensated cirrhosis. (2023) (0)
Tips improves survival in Budd-Chiari Syndrome (BCS) (2000) (0)
Chapter 45 – Portal and Splenic Vein Thrombosis (2012) (0)
40 PREDICTING SURVIVAL IN PORTAL HYPERTENSION: HVPG, CHILD-PUGH, OR MELD? (2004) (0)
[Efficacy of laparoscopy in the diagnosis of ascites of indeterminate origin]. (1988) (0)
287 Predicting survival in portal hypertension: HVPG, child-pugh, or MELD? (2003) (0)
Budd-Chiari Syndrome 13 (2011) (0)
[Influence of blood coagulation disorders on hepatic vascular diseases and therapeutic possibilities]. (2004) (0)
Best Practice & Research Clinical Gastroenterology (2013) (0)
174 VON WILLEBRAND FACTOR LEVELS CORRELATE WITH THE SEVERITY OF PORTAL HYPERTENSION AND INDEPENDENTLY PREDICT THE CLINICAL OUTCOME OF CIRRHOTIC PATIENTS WITH PORTAL HYPERTENSION (2010) (0)
Bacterial deoxyribonucleic is frequent in blood samples of patients with compensated cirrhosis and obesity and is associated with lack of decrease of portal pressure after an intensive lifestyle intervention (2017) (0)
766 Early lobular necrosis and living donor liver transplantation are strong predictors of severe HCV recurrence after liver (2003) (0)
FRI-434-Role of next generation sequencing in the etiological diagnosis of splanchnic venous thrombosis (2019) (0)
THU-092-Role of endothelial mitophagy during endothelial dysfunction and liver fibrosis (2019) (0)
TIPS: Primary Therapy or Rescue in Treatment of Acute Variceal Hemorrhage (2014) (0)
S1918 A Hemodynamic Response to Treatment With Non-Selective Beta-Blockers Protects Against Worsening of Thrombocytopenia in Cirrhosis (2010) (0)
BASIC AND TRANSLATIONAL — LIVER Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension (0)
FRI-120-Structural liver disease rather than portal hypertension is the predominant factor for hepatic macrophage activation in patients with cirrhosis, portal vein thrombosis and idiopathic portal hypertension (2019) (0)
Consensus Statements: Management of the Acute Bleeding Episode (2016) (0)
EASL Recognition Award Recipient 2015: Prof. Dominique C. Valla. (2015) (0)
198 RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS FOR THE REDUCTION OF PORTAL PRESSURE: A META-ANALYSIS AND SYSTEMATIC REVIEW (2010) (0)
Role of Circulating Propionate in Portal Hypertension in Cirrhosis (2016) (0)
Reply: To PMID 23058320. (2013) (0)
178 COMPARISON OF ULTRASONOGRAPHIC EVALUATION OF LIVER SURFACE AND TRANSIENT ELASTOGRAPHY IN THE DIAGNOSIS OF CIRRHOSIS AND PORTAL HYPERTENSION (2009) (0)
SELECTIVE INDUCTION OF ETB RECEPTORS IN MESENTERIC VEINS DURING ENDOTOXEMIA.: 145 (1998) (0)
Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?": pTIPS for variceal bleeding in ACLF patients: when and why? (2020) (0)
606 LIVER ENDOTHELIAL DYSFUNCTION AFTER LPS ADMINISTRATION: A ROLE FOR INDUCIBLE-NITRIC OXIDE SYNTHASE (2011) (0)
Liver Transplant for Porto-sinusoidal Vascular Disease: Long-term Outcome (2021) (0)
Molecular abnormalities in portal hypertension: diagnostic, prognostic and therapeutic implications (2012) (0)
Is it necessary to endoscopically screen all patients with hepatitis C and advanced fibrosis for esophageal varices? (2007) (0)
Portal vein thrombosis: A predictable milestone in cirrhosis? q (2009) (0)
Corrigendum to: "Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury" [J Hepatol (2019) 458-469]. (2020) (0)
Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis (2011) (0)
911 THE ABIC SCORE: A NEW TOOL FOR PROGNOSTIC STRATIFICATION OF PATIENTS WITH ALCOHOLIC HEPATITIS (2008) (0)
SAT-380-Liver-resident memory CD8 T cells do not egress into hepatic venous blood (2019) (0)
Haemodynamic Assessment of Portal Hypertension (2008) (0)
Utility of duplex sonography predicting TIPS dysfunction (2003) (0)
531 EARLY IDENTIFICATION OF TWO PATTERNS OF HEPATITIS C RECURRENCE (RAPID AND SLOW PROGRESSORS) AFTER LIVER TRANSPLANTATION: A PROSPECTIVE LONG-TERM FOLLOW-UP STUDY (2011) (0)
98. Portal hypertension (2012) (0)
621 IMPROVING RISK PREDICTION IN ACUTE VARICEAL BLEEDING WITH OBJECTIVE VARIABLES: THE ROLE OF MELD (2013) (0)
"The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study": reply. (2023) (0)
Physiology of the Splanchnic and Hepatic Circulations (2011) (0)
Simvastatin ameliorates the sinusoidal microcirculatory phenotype, fibrosis and portal hypertension in aged cirrhotic rats (2017) (0)
Risk of bleeding in cirrhotic patients treated with rivaroxaban (2017) (0)
Enhanced release of vasoconstrictors (2004) (0)
Simvastatin Impedes the Endotoxin-Induced Aggravation of Hepatic Microvascular Dysfunction in Two Animal Models of Liver Cirrhosis (2016) (0)
[198] ROLE OF GTP CYCLOHYDROLASE AND TETRAHYDROBIOPTERIN IN THE REGULATION OF HEPATIC VASCULAR TONE (2007) (0)
Hemodynamic effects of albumin administration in spontaneous bacterial peritonitis (2002) (0)
JAK2 Germline Genetic Variation In Budd-Chiari Syndrome and Portal Vein Thrombosis (2010) (0)
Autophagy regulates endothelial dysfunction and hepatic fibrosis development (2017) (0)
Liver: Can we identify failure to control acute variceal bleeding? (2014) (0)
Fibrinogen γ9 In the Budd-Chiari Syndrome: Results From a Multicenter Case-Control Study (2010) (0)
INFLUENCE OF ISCHEMIA/REPERFUSION (I/R) AND ENDOTOXIN ON ENDOTHELIN (ET) RECEPTORS IN RAT LIVERS.: 141 (1998) (0)
Aphasia in a patient with acute hepatic encephalopathy associated with multifocal cortical brain lesions. (2016) (0)
Congenital Extrahepatic Portosystemic Shunts: Abernethy Malformation (2021) (0)
944 PATIENTS WITH CIRRHOSIS WHO FAILED PRIMARY PROPHYLAXIS WITH NON-SELECTIVE BETA-BLOCKERS HAVE AN INCREASED RISK OF REBLEEDING DESPITE ADDING ENDOSCOPIC VARICEAL LIGATION (2011) (0)
The Treatment and Prevention of Variceal Bleeding (2011) (0)
276 PRELIMINARY EFFICACY AND SAFETY OF REPEATED ORAL DOSES OF NCX-1000 FOR THE TREATMENT OF PORTAL HYPERTENSION. A DOUBLE-BLIND, PROOF OF CONCEPT, DOSE ESCALATING STUDY (2008) (0)
Reply to: ''Effect of albumin on survival in septic cirrhotic patients other than spontaneous bacterial peritonitis. The question remains open'' (2013) (0)
Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies (2017) (0)
Endovascular Assessment of Liver Hemodynamics in Cirrhotic Patients with Portal Hypertension. (2022) (0)
PostersPoster Session – Friday, April 20, 201202c. Cirrhosis and ITS Complications: Bleeding661 USE OF EARLY-TIPS FOR HIGH-RISK VARICEAL BLEEDING. RESULTS OF A POST-RCT SURVEILLANCE STUDY (2012) (0)
Idiopathic Portal Hypertension (Portosinusoidal Disease) (2018) (0)
Reply to "Liver Transplantation for Porto-sinusoidal Vascular Liver Disorder: Long-term Outcome". (2023) (0)
Reply: (2019) (0)
Should Prognostic Variables be Used to Direct Patient Management in the Acute Setting (2010) (0)
193 RELIABILITY OF THE ESTIMATION OF HEPATIC BLOOD FLOW (HBF) BY DOPPLER ULTRASOUND IN PATIENTS WITH CIRRHOTIC PORTAL HYPERTENSION: COMPARISON WITH HBF BY INDOCYANINE GREEN (2013) (0)
Reply (2016) (0)
Primary Budd-Chiari Syndrome. (2023) (0)
Refractory Variceal Bleeding: When First Endoscopy Fails, What Next? (2017) (0)
Reply to: "Calreticulin mutations and their importance in Budd-Chiari syndrome". (2017) (0)
451 CLINICAL, HISTOLOGICAL AND HEMODINAMIC OUTCOMES IN HCV-INFECTED LIVER TRANSPLANT RECIPIENTS TREATED WITH PEGILATED INTERFERON PLUS RIBAVIRIN (2009) (0)
Increased variability and loss of accurracy of hepatic hemodynamic measurements under deep sedation in patients with portal hypertension: 3AP4-3 (2011) (0)
Reply to: Correspondence on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis". (2020) (0)
[Endoscopic ligature of esophageal varices in the treatment of portal hypertension]. (2007) (0)
Non-invasive pulsed-doppler evaluation of the patency and blood flow in distal spleno-renal shunts. Comparisons with direct measurements at catheterization (1989) (0)
P517 EFFECTS OF SAPROPTERIN ON PORTAL AND SYSTEMIC HEMODYNAMICS IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION: A BICENTRIC DOUBLE-BLIND PLACEBO CONTROLLED STUDY (2014) (0)
SAT-058-In hepatic cirrhosis, the systemic levels of short chain fatty acids inversely correlate with the level of endotoxemia, and are negatively associated with an increased inflammatory response, impaired liver function and a higher HVPG (2019) (0)
757 3-DAY ADMINISTRATION OF A HIGH FAT DIET INDUCES HEPATIC STEATOSIS AND LIVER ENDOTHELIAL INSULIN RESISTANCE (2009) (0)
Noninvasive tests in the post–liver transplantation setting (2007) (0)
Preemptive TIPS in Child-Pugh C patients. (2019) (0)
TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis (2023) (0)
Early ALT elevation is highly predictive of severe fibrosis and portal hypertension one year after liver transplantation in HCV-infected patients (2003) (0)
Reply (2017) (0)
P1026: COMPARATIVE GENOMIC PROFILING OF MYELOPROLIFERATIVE NEOPLASMS PRESENTING WITH AND WITHOUT SPLANCHNIC VEIN THROMBOSIS (2022) (0)
[Information for patients. Anticoagulation for thrombosis of the portal vein in cirrhosis]. (2014) (0)
173 RIGTH ATRIAL PRESSURE IS NOT ADEQUATE TO CALCULATE THE PORTAL PRESSURE GRADIENT IN CIRRHOSIS. A CLINICAL-HEMODYNAMIC CORRELATION STUDY (2010) (0)
Budd-Chiari Syndrome: Hepatic Venous Outflow Tract Obstruction (2021) (0)
Tips in Budd Chiari Syndrome: Long-term results in 124 patients and evaluation of prognostic factors: A multicentre study (2007) (0)
elastography in clinically doubtful cirrhosis q (2010) (0)
Preemptive TIPS for the treatment of bleeding from gastric fundal varices: results of a randomized-controlled trial (2023) (0)
523 HEMODYNAMIC EFFECTS OF TEZOSENTAN, A DUAL ENDOTHELIN RECEPTOR ANTAGONIST, IN PATIENTS WITH CIRRHOSIS (2010) (0)
Letter to the Editor: Salvage TIPS in Patients With Cirrhosis With Variceal Bleeding: MELD, Lactates, and “à la Carte” Decision (2021) (0)
SVR to DAA does not affect the risk of portal vein thrombosis in patients with advanced chronic liver disease (2020) (0)
Pregnancy in women with idiopathic non-cirrhotic portal hypertension: results of a multicentric European study on maternal and fetal management and outcome (2017) (0)
PS-023-Factors predicting survival in patients with high-risk acute variceal bleeding treated with pre-emptive (Early)-TIPS (2019) (0)

This paper list is powered by the following services:

Juan‐carlos García‐pagán's Academic­Influence.com Rankings

Juan‐carlos García‐pagán's Degrees

Why Is Juan‐carlos García‐pagán Influential?

Juan‐carlos García‐pagán's Published Works

Published Works

Juan‐carlos García‐pagán's AcademicInfluence.com Rankings